Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TIMP-GLIA in Celiac Disease
NCT03486990Phase 1Completed
- Sponsor
- Takeda
- Start
- Jan 2018
- Primary completion
- May 2019
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of CNP-101 in celiac disease (9 arms), sponsored by Takeda. Primary endpoints: Treatment-emergent Adverse Events, Grade 3 or Higher Treatment-emergent Adverse Events and 8 more. Started Jan 2018; status: completed.
02
Drugs
CNP-101
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT03486990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486990.